ChromaDex CFO Brianna Gerber resigns effective July 12; consulting transition through Aug 12

Niagen Bioscience, Inc.

CFO & CAO Brianna Gerber resigns effective July 12, 2024; company beginning search for replacement.
Post-resignation consulting agreement through Aug 12, 2024; $1,000 consulting fee.
Outstanding stock options and RSUs continue to vest during consulting period per existing equity plan terms.
Gerber confirms resignation is without Good Reason; no severance benefits under employment agreement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brianna Gerber

Chief Financial Officer and Chief Accounting Officer

NAGE · Niagen Bioscience, Inc.

Effective: 2024-07-12
Filed: June 25, 2024, 7:59 PM ET

On June 19, 2024, Brianna Gerber, the Chief Financial Officer and Chief Accounting Officer of ChromaDex Corporation (the “Company”), informed the Company that she will be resigning from her roles with the Company, effective July 12, 2024 (the “Separation Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brianna Gerber departed as Chief Financial Officer and Chief Accounting Officer at Niagen Bioscience, Inc..

Action: resigning
Role: Chief Financial Officer and Chief Accounting Officer

Exact text from the filing

On June 19, 2024, Brianna Gerber, the Chief Financial Officer and Chief Accounting Officer of ChromaDex Corporation (the “Company”), informed the Company that she will be resigning from her roles with the Company, effective July 12, 2024 (the “Separation Date”).

View on SEC.gov

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-029936

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.